

TAXOL APPROVED FOR BREAST CANCER

25-04-1994 Comments (0)

Bristol-Myers Squibb has received approval from the US Food and Drug Administration for its anticancer drug Taxol (paclitaxel) in the treatment of refractory breast cancer.

The supplemental indication approval, four months after its recommendation, is for treatment of the disease within six months of combination chemotherapy failure, provided that prior therapy has included an anthracycline unless clinically contraindicated. The approved treatment dosage is 175mg/m² infused over three hours every three weeks.

◁ Bristol-Myers Squibb ◁ Paclitaxel ◁ Taxol
